Trial Profile
AN OBSERVATIONAL SAFETY STUDY FOR PREVENAR 13 AMONG CHINESE CHILDREN
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Sep 2021
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 14 Jan 2021 Status changed from active, no longer recruiting to completed.
- 10 Sep 2018 New trial record